JEFFREY M. JONAS - 27 Apr 2022 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol: SAGE
Transactions as of: 27 Apr 2022
Net transactions value: +$13,925
Form type: 4
Filing time: 29 Apr 2022, 08:40:31 UTC
Previous filing: 18 Feb 2022
Next filing: 13 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SAGE	Common Stock	Options Exercise	$13,925	+30,944	+36%	$0.4500^*	115,807	27 Apr 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Options Exercise	$0	-30,944	-73%	$0.000000	11,643	27 Apr 2022	Common Stock	30,944	$0.4500	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2011 Stock Option and Incentive Plan. The option vested in full on August 12, 2017.